Systemic and intratumoral 9-valent human papillomavirus vaccine treatment for squamous cell carcinoma in situ in a renal transplant recipient

Nichols, Anna; Bedout, Valeria De; Fayne, Rachel; Burke, George W.; Kirsner, Robert S.; Ioannides, Tim

doi:10.1016/j.jdcr.2020.02.002

Cited by 10 publications

(10 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Over four months, the patient received two intramuscular and two intratumoral injections with the 9-valent HPV vaccine (Gardasil-9 ® , MSD). Five months after the last injection, the lesion resolved with biopsy-proven histologic cure ( 88 ).…”

Section: Hpv Vaccinementioning

confidence: 99%

Repurposing Infectious Diseases Vaccines Against Cancer

et al. 2021

View full text Add to dashboard Cite

Vaccines used to prevent infections have long been known to stimulate immune responses to cancer as illustrated by the approval of the Bacillus Calmette–Guérin (BCG) vaccine to treat bladder cancer since the 1970s. The recent approval of immunotherapies has rejuvenated this research area with reports of anti-tumor responses with existing infectious diseases vaccines used as such, either alone or in combination with immune checkpoint inhibitors. Here, we have reviewed and summarized research activities using approved vaccines to treat cancer. Data supporting a cancer therapeutic use was found for 16 vaccines. For 10 (BCG, diphtheria, tetanus, human papillomavirus, influenza, measles, pneumococcus, smallpox, typhoid and varicella-zoster), clinical trials have been conducted or are ongoing. Within the remaining 6, preclinical evidence supports further evaluation of the rotavirus, yellow fever and pertussis vaccine in carefully designed clinical trials. The mechanistic evidence for the cholera vaccine, combined with the observational data in colorectal cancer, is also supportive of clinical translation. There is limited data for the hepatitis B and mumps vaccine (without measles vaccine). Four findings are worth highlighting: the superiority of intravesical typhoid vaccine instillations over BCG in a preclinical bladder cancer model, which is now the subject of a phase I trial; the perioperative use of the influenza vaccine to limit and prevent the natural killer cell dysfunction induced by cancer surgery; objective responses following intratumoral injections of measles vaccine in cutaneous T-cell lymphoma; objective responses induced by human papillomavirus vaccine in cutaneous squamous cell carcinoma. All vaccines are intended to induce or improve an anti-tumor (immune) response. In addition to the biological and immunological mechanisms that vary between vaccines, the mode of administration and sequence with other (immuno-)therapies warrant more attention in future research.

show abstract

Section: Hpv Vaccinementioning

confidence: 99%

Repurposing Infectious Diseases Vaccines Against Cancer

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Direct antiviral, antitumor, and immunologic mechanisms have been suggested, but little research has been done in this area. 8 Although we acknowledge that systemic bivalent vaccination (HPV type 16/18) may not be ideal given its comparatively limited protection, in light of the need for long-term immunosuppression, we felt that high-risk subtype protection would be of some value in decreasing the risk of other HPV-associated cancers. Additionally, systemic bivalent HPV vaccination may induce an immunologic response against other alpha-papillomaviruses not specifically targeted by the vaccine, due to similarities in the L1 major capsid proteins shared by members of this genus, which potentially include the low-risk subtypes associated with GCBL.…”

Section: Discussionmentioning

confidence: 99%

“… 9 This has clinically been demonstrated by the response of recalcitrant common warts (not typically caused by HPV types 16/18) to both intralesional and intramuscular bivalent vaccination. 8 …”

Section: Discussionmentioning

confidence: 99%

Giant condyloma of Buschke-Lowenstein in a patient with pemphigus vegetans treated with intralesional and systemic human papillomavirus vaccine

Thomas

Smith-Matthews

2022

JAAD Case Reports

View full text Add to dashboard Cite

“…Indeed, using an identical vaccination protocol, we previously treated a patient with exceedingly high AK burden (>1,000 AKs), noting marked reduction in lesion number and improved skin texture over 1 year [ 6 ]. Interestingly, systemic and intratumoral use of HPV vaccines were recently described in the context of KC for 4 immunocompetent and 1 immunocompromised patient [ 7 , 8 , 9 , 10 ]. In comparison with KCs, an accelerated response seemed to occur in precursor AKs.…”

Section: Discussionmentioning

confidence: 99%

Off-Label 9-Valent Human Papillomavirus Vaccination for Actinic Keratosis: A Case Series

et al. 2021

View full text Add to dashboard Cite

Background: The suspected link between human papillomavirus (HPV) and the development of premalignant and malignant skin lesions remains inadequately examined in clinical settings. This case series describes HPV vaccination as an off-label adjuvant therapy for actinic keratosis (AK). Methods: Twelve immunocompetent AK patients underwent HPV vaccination at a private dermatology clinic in Naestved, Denmark. Prior to vaccination, all patients demonstrated a high AK burden that required regular control visits. At 0, 2, and 6 months, the patients received an intramuscular injection of a commercially available 9-valent HPV vaccine. Concurrently, patients continued conventional AK therapies at 3-month intervals. Clinical response, consisting of reduction in AK number and general change in skin appearance, was assessed by a dermatologist over 12 months following first vaccination. Results: All patients (mean age 76.2 years; 10 M and 2 F) completed the vaccine schedule. Overall, an average 85% reduction in total AK burden was recorded 12 months after beginning vaccination. Median AK burden thus fell from 56 (IQR: 44–80) to 13.5 (IQR: 1–18) lesions after 12 months. Lesion reduction was observable by the second inoculation at month 2 (34 AKs; IQR 22–80), continuing steadily until month 6 (15 AKs; IQR 5–30) and plateauing between 6 and 12 months. Clinically, HPV vaccination elicited fading of lesions’ erythematous background after the first dose, often followed by sloughing of hyperkeratotic elements in subsequent weeks. Patients reported no adverse effects related to HPV vaccination. Conclusion: This case series introduces the possibility that 9-valent HPV vaccination in combination with conventional treatments may be used as a therapeutic strategy for AK.

show abstract

Systemic and intratumoral 9-valent human papillomavirus vaccine treatment for squamous cell carcinoma in situ in a renal transplant recipient

Cited by 10 publications

References 4 publications

Repurposing Infectious Diseases Vaccines Against Cancer

Repurposing Infectious Diseases Vaccines Against Cancer

Giant condyloma of Buschke-Lowenstein in a patient with pemphigus vegetans treated with intralesional and systemic human papillomavirus vaccine

Off-Label 9-Valent Human Papillomavirus Vaccination for Actinic Keratosis: A Case Series

Contact Info

Product

Resources

About